**Accelerating vaccine process development and manufacturing: innovative approaches and challenges**

Preventable diseases vaccines save millions of lives but are not always delivered when needed to a large fraction of the population. In addition, there is a number of infectious diseases that still remain without cure or vaccine. Innovations in process development and manufacturing are unavoidable to enable release of existing and novel vaccines and their delivery where and when they are mostly needed.

This presentation will outline where innovative approaches and technologies while developing and/or optimizing the process and at manufacturing scale can accelerate clinical phases and compress the time to market of highly needed vaccines. Furthermore, using case studies like Ebola and influenza outbreaks, challenges will also be highlighted in pandemic situations and approaches will be discussed on how to alleviate roadblocks and be better prepared to manufacture vaccines in urgent situations.

Anissa Boumlic-Courtade Bio

Anissa Boumlic-Courtade, PhD is Associate Director for the vaccine initiative in EMEA with Merck. Dr. Boumlic-Courtade joined Merck in 2009 (formerly Millipore) after research experience in various institute including Pasteur Institute of Athens and the CNRS (National Center for Research, France). She has held various positions focused on downstream processing, virus safety, and monoclonal antibody and vaccine process development and manufacturing. Dr. Anissa Boumlic-Courtade holds a M. Sc. in Biotechnology Engineering from the Ecole Supérieure de Biotechnologie (ESBS) de Strasbourg (France) and a PhD in Molecular Biology & Biochemistry specialized in Virology from the University of Strasbourg co-directed with the University of Thessaly (Greece).